| 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 000930 | 中粮科技 | > 20.53万 | 0.15% | -183.82万 | -1.32% | 163.29万 | 1.17% | | 000803 山高环能 | | 11.49万 | 0.13% | 548.25万 | 6.08% | -559.74万 | -6.20% | | 300664 鹏鹞环保 | | -205.79万 | -3.80% | 271.50万 | 5.01% | -65.71万 | -1.21% | | 300072 海新能科 | | -394.39万 | -3.29% | -65.70万 | -0.55% | 460.09万 | 3.84% | | 603822 | ST嘉澳 | -467.68万 | -7.97% | -354.57万 | -6.04% | 822.25万 | 14.01% | | 603334 | 丰倍生物 ...

证券代码：688196 证券简称：卓越新能 公告编号：2026-003 龙岩卓越新能源股份有限公司 关于开立募集资金理财产品专用结算账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 龙岩卓越新能源股份有限公司（以下简称"公司"或"卓越新能"）于 2025 年 10 月 30 日召开第五届董事会第十三次会议，审议通过了《关于使用部 分暂时闲置募集资金进行现金管理的议案》，同意在确保不影响募集资金投资 项目实施及募集资金安全的情况下，拟使用额度不超过人民币 47,000 万元的部 分暂时闲置募集资金进行现金管理。本次现金管理决议的有效期限自 2025 年 10 月 30 日起 12 个月内有效。在上述额度和期限范围内，资金可以滚动使用。 具 体 内 容 详 见 公 司 于 2025 年 10 月 31 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《关于使用部分闲置募集资金及自有资金进行现金 管理的公告》（公告编号：2025-048）。 公司于 2025 年 11 月 24 日召开 ...

根据投资者关系活动记录表，公司国内现有酯基生物柴油50万吨/年，烃基一线年产10万吨HVO/SAF生产线将于 2026年投产，同时将启动烃基二线的建设。 【国泰海通基础化工团队】卓越新能：2025年公司扣非净利润1.9亿元，较上年同期大幅增长40.95% 公司发布2025年度业绩快报，2025年度营业收入29.42亿元，同比下降17.43%；归母净利润1.7亿元，同比增长 14.16%；扣非净利润1.9亿元，较上年同期大幅增长40.95%。 主要系本年度公司调整经营策略，产品综合毛利有所提高，及公司天然脂肪醇生产线投产。 【国泰海通基础化工团队】卓越新能：2025年公司扣非净利润1.9亿元，较上年同期大幅增长40.95% 公司发布2025年度业绩快报，2025年度营业收入29.42亿元，同比下降17.43%；归母净利润1.7亿元，同比增长 14.16%；扣非净利润1.9亿元，较上年同期大幅增长40.95%。 主要系本年度公司调整经营策略，产品综合毛利有所提高，及公司天然脂肪醇生产线投产。 根 海外多区域产能项目及上下游供应链体系建设也在同步推进中。 ...

2月3日晚间重要公告摘要 | 类型 | 公司 | 主要内容 | | --- | --- | --- | | 聚焦 | 智洋创新 | 筹划购买灵明光子控制权 4日起停牌 | | | 凯龙高科 | 拟购买金旺达70%股权4日起复牌 | | | *ST立方 | 完成停牌核查 4日起复牌 | | 业绩精选 | 药康生物 业绩快报 | 2025年净利润同比增长31.49% | | | 卓越新能 业绩快报 | 2025年净利润同比增长14.16% | | | 旭光电子 | 拟定增募资不超10亿元 | | 定增&重组 | *ST블降 | 公司重整计划获得法院裁定批准 | | | *ST金灵 | 公司重整计划获得法院裁定批准 | | | 韩建河山 | 拟购买兴福新材99.9978%股份 4日起复牌 | | | 嘉事堂 | 控股股东拟变更为同仁堂集团 4日起复牌 | | | 富临精工 | 拟与宁德时代共同对子公司江西升华增资扩股 | | | 微芯生物 | 与Nizhpharm就西达本胺签署许可及分销协议 | | 重要事项 | 汽解放 | 拟使用不超100亿元自有资金进行委托理财 | | | 宁德时代 | 已耗资43.86亿元回 ...

| | | 2月3日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 杰普特 | 光通信相关业务收入占公司总营业收入的比例不足5% | | | 沃格光电 | 航天CPI产品尚未实现量产 | | 项目投资 | 黄山旅游 | 拟约5.3亿元投资建设黄山滨江东路12号酒店项目 | | 合同中标 | 宜通世纪 | 预中标1.07亿元项目 | | 股权转让 | 浙江东方 | 东方产融损1.08亿元收购国金租赁5.98%股份 | | 业绩 | 卓越新能 | 2025年度净利润1.7亿元,同比增长14.16% | | 回购 | 宇新股份 | 累计回购1. 4003%股份 回购股份方案已实施完毕 | | 增减持 | 商络电子 | 实际控制人拟减持不超过3%股份 | | 其他 | 旭光电子 | 拟定增募资不超10亿元 | | | 华发股份 | 拟定增募资不超30亿元 广场容量 | 【热点】 沃格光电(603773.SH)：航天CPI产品尚未实现量产 燕麦科技(688312.SH)：收购的AXIS-TEC具有硅光晶圆测试的相关产品，目前销售收入占比不足1% 炬光科技(6 ...

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

智通财经APP讯，卓越新能(688196.SH)披露2025年度业绩快报，2025年度营业总收入29.42亿元，同比 下降17.43%;归属于母公司所有者的净利润1.7亿元，同比增长14.16%。 公司2025年度经营业绩较上年同期有所增长，主要系本年度公司调整经营策略，产品综合毛利有所提 高，及公司天然脂肪醇生产线投产。 ...

Financial Performance - Total revenue for 2025 was RMB 294,224.61 million, a decrease of 17.43% compared to RMB 356,332.52 million in the previous year[4] - Operating profit increased by 15.83% to RMB 17,847.86 million from RMB 15,408.38 million year-on-year[4] - Net profit attributable to shareholders of the parent company rose by 14.16% to RMB 17,011.54 million from RMB 14,901.88 million[4] - Net profit excluding non-recurring gains and losses increased significantly by 40.95% to RMB 19,008.08 million, driven by higher sales profits[6] - Basic earnings per share increased to RMB 1.40, up 12.90% from RMB 1.24 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 402,326.40 million, reflecting a growth of 12.81% from RMB 356,631.14 million at the beginning of the period[4] - Equity attributable to shareholders of the parent company increased by 14.40% to RMB 319,492.01 million from RMB 279,272.77 million[5] Return on Investment - The company’s weighted average return on net assets improved by 0.43 percentage points to 5.88%[4] Operational Insights - The increase in operating performance was attributed to strategic adjustments and improved product gross margins, along with the commissioning of the natural fatty alcohol production line[6] - There are no significant uncertainties affecting the accuracy of the performance report[7]

格隆汇2月3日｜卓越新能(688196.SH)公告称，公司2025年营业总收入29.42亿元，同比下降17.43%；归 属于母公司所有者的净利润1.7亿元，同比增长14.16%。 ...

格隆汇2月3日丨卓越新能(688196.SH)公布2025年度业绩快报公告，报告期实现营业总收入29.42亿元， 同比下降17.43%；归属于母公司所有者的净利润1.7亿元，同比增长14.16%；基本每股收益1.40元。公 司2025年度经营业绩较上年同期有所增长，主要系本年度公司调整经营策略，产品综合毛利有所提高， 及公司天然脂肪醇生产线投产。 ...